OKYO Pharma CEO buys 15,000 shares in market

OKYO Pharma Ltd reported that Chief Executive Officer Robert John Dempsey purchased 15,000 shares of common stock on July 22, 2026 at $1.539 per share in a transaction coded as a purchase in an open market or private transaction.

Accepted by SEC EDGAR 08/07/2026 - 04:15 PM EDT Learn about SEC filing dates

Rhea-AI Filing Summary

OKYO Pharma Ltd reported that Chief Executive Officer Robert John Dempsey purchased 15,000 shares of common stock on July 22, 2026 at $1.539 per share in a transaction coded as a purchase in an open market or private transaction. Following this trade, he directly holds 15,000 shares. The Form 4/A states it amends the July 23, 2026 filing solely to correct the transaction code, with no other transactions affected and the Rule 10b5-1 trading-plan box left unchecked.

Insider Trade Summary

Net Buyer: 15,000 shares

Net Buy 1 txn

Insider Dempsey Robert John

Role CHIEF EXECUTIVE OFFICER

Bought 15,000 shs ($23K)

Type	Security	Shares	Price	Value
Purchase	COMMON STOCK	15,000	$1.539	$23K

Holdings After Transaction: COMMON STOCK — 15,000 shares (Direct)

Key Figures

Shares purchased: 15,000 shares Purchase price: $1.539 per share Shares owned after transaction: 15,000 shares +1 more

4 metrics

Shares purchased 15,000 shares Non-derivative common stock purchase on July 22, 2026

Purchase price $1.539 per share Price per share for the 15,000-share common stock purchase

Shares owned after transaction 15,000 shares Direct common stock holdings reported following the purchase

Net buy shares 15,000 shares Net buy direction from transaction summary for this filing

Key Terms

Form 4/A, open market or private transaction, non-derivative, Rule 10b5-1

4 terms

Form 4/A regulatory

"This Form 4/A amends the Form 4 filed on July 23, 2026"

Form 4/A is an amended filing that corrects or updates an earlier Form 4, the mandatory report that insiders (like company executives, directors, or large shareholders) must file when their ownership stakes change. Think of it as an edited receipt showing who bought or sold stock and when; investors use it to track insider confidence, detect potential conflicts, and spot trading patterns that might signal future company prospects.

open market or private transaction financial

"Purchase in open market or private transaction"

non-derivative financial

"transaction_type: "non-derivative""

Rule 10b5-1 regulatory

"aff_10b5_one is the filing's document-level Rule 10b5-1 checkbox"

Rule 10b5-1 is a regulation that allows company insiders to buy or sell their shares at predetermined times, even if they have access to non-public information. It acts like setting a schedule in advance for transactions, helping prevent accusations of unfair trading. This rule provides a way for insiders to plan trades transparently, giving investors confidence that these transactions are not based on hidden information.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did OKYO report in this Form 4/A?

OKYO reported that CEO Robert John Dempsey purchased 15,000 shares of common stock on July 22, 2026 at $1.539 per share. The trade is classified as a purchase in an open market or private transaction and is held directly.

Who is the insider involved in the latest OKYO (OKYO) filing?

The insider is Robert John Dempsey, Chief Executive Officer and director of OKYO Pharma Ltd. He reported a direct purchase of 15,000 common shares on July 22, 2026, bringing his reported direct holdings to 15,000 shares after the transaction.

How many OKYO (OKYO) shares does the CEO hold after this transaction?

After the reported trade, CEO Robert John Dempsey directly holds 15,000 shares of OKYO Pharma common stock. This reflects the full 15,000-share purchase on July 22, 2026, with the post-transaction balance shown as 15,000.0000 shares in the filing.

What price did the OKYO (OKYO) CEO pay per share in the reported trade?

The CEO’s reported purchase price was $1.539 per share for 15,000 OKYO Pharma common shares. The transaction is identified as a non-derivative open market or private purchase, with the price explicitly noted as a per-share value in the filing data.

Was the OKYO (OKYO) CEO’s share purchase under a Rule 10b5-1 plan?

The filing indicates the trade was not under a Rule 10b5-1 trading plan, as the relevant checkbox is unchecked. The transaction is instead reported as a discretionary open market or private purchase of 15,000 shares on July 22, 2026.

What change does this Form 4/A amendment make for OKYO (OKYO)?

The Form 4/A only corrects the transaction code for the July 22, 2026 purchase. It states that this amendment is solely to fix that code, with no other transactions or amounts from the prior Form 4 affected or revised.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Dempsey Robert John

(Last) (First) (Middle)

14-15 CONDUIT ST

(Street)

LONDON X0 W1S 2XJ

(City) (State) (Zip)

UNITED KINGDOM

(Country)

2. Issuer Name and Ticker or Trading Symbol
OKYO Pharma Ltd [ OKYO ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	CHIEF EXECUTIVE OFFICER

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
07/22/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)
07/23/2026

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
COMMON STOCK	07/22/2026		P		15,000	A	$1.539	15,000	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

Remarks:

This Form 4/A amends the Form 4 filed on July 23, 2026 solely to correct the transaction code associated with this open market purchase. No other reported transactions are affected by this amendment.

	/s/ Robert Dempsey	08/07/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)